Compare ARK Genomic Revolution ETF (ARKG) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Prologis Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.8, while Prologis Inc trades at $141.04 (market cap $131.34B). The key difference: Prologis Inc pays a 3.04% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | PLD | |
|---|---|---|
Sector | Sector/Thematic | Real Estate |
52-Week High | $43.57 | $148.74 |
52-Week Low | $23.09 | $104.08 |
Market Cap | — | $131.34B |
Enterprise Value | — | $165.21B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Prologis (PLD) trades at $140.87, down 0.35% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $155.20. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.05 exceeding the $0.806 estimate. Fundamentals show robust revenue growth to $8.79B in 2025 and a high net income margin of 41.54%, though valuation ratios like a P/E of 35.39 are elevated. Recent news highlights a rejected $16.9 billion takeover bid for SEGRO, indicating aggressive growth ambitions.
The outlook for PLD is positive, supported by embedded rent growth, a $42B development pipeline, and expansion into data centers. Key risks include rising debt levels, with debt-to-asset ratio increasing to 37.2% in 2025, and integration challenges from potential acquisitions. Analyst sentiment is bullish with 57% buy ratings, but investors should monitor execution on strategic initiatives and macroeconomic impacts on logistics demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
